Literature DB >> 15024927

Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment.

Toby Leslie1, Mohammad Abdur Rab, Hayat Ahmadzai, Naeem Durrani, Mohammad Fayaz, Jan Kolaczinski, Mark Rowland.   

Abstract

The only available treatment that can eliminate the latent hypnozoite reservoir of vivax malaria is a 14 d course of primaquine (PQ). A potential problem with long-course chemotherapy is the issue of compliance after clinical symptoms have subsided. The present study, carried out at an Afghan refugee camp in Pakistan, between June 2000 and August 2001, compared 14 d treatment in supervised and unsupervised groups in which compliance was monitored by comparison of relapse rates. Clinical cases recruited by passive case detection were randomised by family to placebo, supervised, or unsupervised groups, and treated with chloroquine (25 mg/kg) over 3 days to eliminate erythrocytic stages. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency were excluded from the trial. Cases allocated to supervision were given directly observed treatment (0.25 mg PQ/kg body weight) once per day for 14 days. Cases allocated to the unsupervised group were provided with 14 PQ doses upon enrollment and strongly advised to complete the course. A total of 595 cases were enrolled. After 9 months of follow up PQ proved equally protective against further episodes of P. vivax in supervised (odds ratio 0.35, 95% CI 0.21-0.57) and unsupervised (odds ratio 0.37, 95% CI 0.23-0.59) groups as compared to placebo. All age groups on supervised or unsupervised treatment showed a similar degree of protection even though the risk of relapse decreased with age. The study showed that a presumed problem of poor compliance may be overcome with simple health messages even when the majority of individuals are illiterate and without formal education. Unsupervised treatment with 14-day PQ when combined with simple instruction can avert a significant amount of the morbidity associated with relapse in populations where G6PD deficiency is either absent or readily diagnosable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024927     DOI: 10.1016/s0035-9203(03)00041-5

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  28 in total

Review 1.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 2.  Plasmodium vivax treatments: what are we looking for?

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey; Lorenz von Seidlein
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

Authors:  Ghulam Rahim Awab; Sasithon Pukrittayakamee; Mallika Imwong; Arjen M Dondorp; Charles J Woodrow; Sue Jean Lee; Nicholas P J Day; Pratap Singhasivanon; Nicholas J White; Faizullah Kaker
Journal:  Malar J       Date:  2010-04-21       Impact factor: 2.979

4.  Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.

Authors:  Brioni R Moore; Sam Salman; John Benjamin; Madhu Page-Sharp; Leanne J Robinson; Elizabeth Waita; Kevin T Batty; Peter Siba; Ivo Mueller; Timothy M E Davis; Inoni Betuela
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 5.  Primaquine treatment and relapse in Plasmodium vivax malaria.

Authors:  Kumar Rishikesh; Kavitha Saravu
Journal:  Pathog Glob Health       Date:  2016-02-18       Impact factor: 2.894

6.  Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study.

Authors:  Peter Van den Eede; Veronica E Soto-Calle; Christopher Delgado; Dionicia Gamboa; Tanilu Grande; Hugo Rodriguez; Alejandro Llanos-Cuentas; Jozef Anné; Umberto D'Alessandro; Annette Erhart
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

7.  Clinical trial of extended-dose chloroquine for treatment of resistant falciparum malaria among Afghan refugees in Pakistan.

Authors:  Natasha Howard; Naeem Durrani; Sanda Sanda; Khalid Beshir; Rachel Hallett; Mark Rowland
Journal:  Malar J       Date:  2011-06-23       Impact factor: 2.979

8.  Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand.

Authors:  Nardlada Khantikul; Piyarat Butraporn; Han S Kim; Somjai Leemingsawat; M A Sandra B Tempongko; Wannapa Suwonkerd
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

9.  Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.

Authors:  Angela Devine; Katherine E Battle; Niamh Meagher; Rosalind E Howes; Saber Dini; Peter W Gething; Julie A Simpson; Ric N Price; Yoel Lubell
Journal:  PLoS Med       Date:  2021-06-01       Impact factor: 11.069

10.  Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.

Authors:  Renata S Pedro; Lusiele Guaraldo; Dayse P Campos; Anielle P Costa; Cláudio T Daniel-Ribeiro; Patrícia Brasil
Journal:  Malar J       Date:  2012-07-28       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.